22 Jul PolTREG
Daniel Shelly, Ph.D., Chief Business Development Officer
Oct. 5 | 5:00pm | FLW Ballroom G
Gdansk Poland
(NASDAQ: PTG)
Immuthera and Poltreg SA (Parent) are pioneers in T-Regulatory cell therapy (Tregs). In the US, Immuthera is advancing the novel, first-in-class CD6-CTLA4 CAR-Treg which has been clinically validated in 6 cGVHD patients and has a second IND in Stage 3 T1D approved. Immuthera intends to open INDs for dermatological and neuroinflammatory basket studies. PolTREG is a fully integrated clinical stage company with extensive Treg experience, a pipeline of advanced Treg & mRNA immunotherapies, and commercial stage cGMP manufacturing. Our lead asset, PTG-007+Rituximab is in a Phase II study in presymptomatic Stage 1 T1D down to 3 yrs old. PTG-007 + Rituximab was deemed eligible for a European Marketing Authorization (MAA expected Q4 2027). Our anti-MOG CAR-Treg for Neuroinflammatory diseases will enter the clinic in Q4 2026. Our multi-edited Allogeneic CAR-Tregs and our In-vivo antigen specific Treg platforms are in late preclinical development.